Cargando…

Ferumoxytol-enhanced magnetic resonance imaging assessing inflammation after myocardial infarction

OBJECTIVES: Macrophages play a central role in the cellular inflammatory response to myocardial infarction (MI) and predict subsequent clinical outcomes. We aimed to assess temporal changes in cellular inflammation and tissue oedema in patients with acute MI using ultrasmallsuperparamagnetic particl...

Descripción completa

Detalles Bibliográficos
Autores principales: Stirrat, Colin G, Alam, Shirjel R, MacGillivray, Thomas J, Gray, Calum D, Dweck, Marc R, Raftis, Jennifer, Jenkins, William SA, Wallace, William A, Pessotto, Renzo, Lim, Kelvin HH, Mirsadraee, Saeed, Henriksen, Peter A, Semple, Scott IK, Newby, David E
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Heart 2017
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5629948/
https://www.ncbi.nlm.nih.gov/pubmed/28642288
http://dx.doi.org/10.1136/heartjnl-2016-311018
_version_ 1783269152813744128
author Stirrat, Colin G
Alam, Shirjel R
MacGillivray, Thomas J
Gray, Calum D
Dweck, Marc R
Raftis, Jennifer
Jenkins, William SA
Wallace, William A
Pessotto, Renzo
Lim, Kelvin HH
Mirsadraee, Saeed
Henriksen, Peter A
Semple, Scott IK
Newby, David E
author_facet Stirrat, Colin G
Alam, Shirjel R
MacGillivray, Thomas J
Gray, Calum D
Dweck, Marc R
Raftis, Jennifer
Jenkins, William SA
Wallace, William A
Pessotto, Renzo
Lim, Kelvin HH
Mirsadraee, Saeed
Henriksen, Peter A
Semple, Scott IK
Newby, David E
author_sort Stirrat, Colin G
collection PubMed
description OBJECTIVES: Macrophages play a central role in the cellular inflammatory response to myocardial infarction (MI) and predict subsequent clinical outcomes. We aimed to assess temporal changes in cellular inflammation and tissue oedema in patients with acute MI using ultrasmallsuperparamagnetic particles of iron oxide (USPIO)-enhanced MRI. METHODS: Thirty-one patients were recruited following acute MI and followed up for 3 months with repeated T2 and USPIO-enhanced T2*-mapping MRI. Regions of interest were categorised into infarct, peri-infarct and remote myocardial zones, and compared with control tissues. RESULTS: Following a single dose, USPIO enhancement was detected in the myocardium until 24 hours (p<0.0001). Histology confirmed colocalisation of iron and macrophages within the infarcted, but not the non-infarcted, myocardium. Following repeated doses, USPIO uptake in the infarct zone peaked at days 2–3, and greater USPIO uptake was detected in the infarct zone compared with remote myocardium until days 10–16 (p<0.05). In contrast, T2-defined myocardial oedema peaked at days 3–9 and remained increased in the infarct zone throughout the 3-month follow-up period (p<0.01). CONCLUSION: Myocardial macrophage activity can be detected using USPIO-enhanced MRI in the first 2 weeks following acute MI. This observed pattern of cellular inflammation is distinct, and provides complementary information to the more prolonged myocardial oedema detectable using T2 mapping. This imaging technique holds promise as a non-invasive method of assessing and monitoring myocardial cellular inflammation with potential application to diagnosis, risk stratification and assessment of novel anti-inflammatory therapeutic interventions. TRIAL REGISTRATION NUMBER: Trial registration number: 14663. Registered on UK Clinical Research Network (http://public.ukcrn.org.uk) and also ClinicalTrials.gov (https://clinicaltrials.gov/ct2/show/NCT02319278?term=DECIFER&rank=2).
format Online
Article
Text
id pubmed-5629948
institution National Center for Biotechnology Information
language English
publishDate 2017
publisher Heart
record_format MEDLINE/PubMed
spelling pubmed-56299482017-10-11 Ferumoxytol-enhanced magnetic resonance imaging assessing inflammation after myocardial infarction Stirrat, Colin G Alam, Shirjel R MacGillivray, Thomas J Gray, Calum D Dweck, Marc R Raftis, Jennifer Jenkins, William SA Wallace, William A Pessotto, Renzo Lim, Kelvin HH Mirsadraee, Saeed Henriksen, Peter A Semple, Scott IK Newby, David E Heart Special Populations OBJECTIVES: Macrophages play a central role in the cellular inflammatory response to myocardial infarction (MI) and predict subsequent clinical outcomes. We aimed to assess temporal changes in cellular inflammation and tissue oedema in patients with acute MI using ultrasmallsuperparamagnetic particles of iron oxide (USPIO)-enhanced MRI. METHODS: Thirty-one patients were recruited following acute MI and followed up for 3 months with repeated T2 and USPIO-enhanced T2*-mapping MRI. Regions of interest were categorised into infarct, peri-infarct and remote myocardial zones, and compared with control tissues. RESULTS: Following a single dose, USPIO enhancement was detected in the myocardium until 24 hours (p<0.0001). Histology confirmed colocalisation of iron and macrophages within the infarcted, but not the non-infarcted, myocardium. Following repeated doses, USPIO uptake in the infarct zone peaked at days 2–3, and greater USPIO uptake was detected in the infarct zone compared with remote myocardium until days 10–16 (p<0.05). In contrast, T2-defined myocardial oedema peaked at days 3–9 and remained increased in the infarct zone throughout the 3-month follow-up period (p<0.01). CONCLUSION: Myocardial macrophage activity can be detected using USPIO-enhanced MRI in the first 2 weeks following acute MI. This observed pattern of cellular inflammation is distinct, and provides complementary information to the more prolonged myocardial oedema detectable using T2 mapping. This imaging technique holds promise as a non-invasive method of assessing and monitoring myocardial cellular inflammation with potential application to diagnosis, risk stratification and assessment of novel anti-inflammatory therapeutic interventions. TRIAL REGISTRATION NUMBER: Trial registration number: 14663. Registered on UK Clinical Research Network (http://public.ukcrn.org.uk) and also ClinicalTrials.gov (https://clinicaltrials.gov/ct2/show/NCT02319278?term=DECIFER&rank=2). Heart 2017-10 2017-06-22 /pmc/articles/PMC5629948/ /pubmed/28642288 http://dx.doi.org/10.1136/heartjnl-2016-311018 Text en © Article author(s) (or their employer(s) unless otherwise stated in the text of the article) 2017. All rights reserved. No commercial use is permitted unless otherwise expressly granted. This is an Open Access article distributed in accordance with the terms of the Creative Commons Attribution (CC BY 4.0) license, which permits others to distribute, remix, adapt and build upon this work, for commercial use, provided the original work is properly cited. See: http://creativecommons.org/licenses/by/4.0/
spellingShingle Special Populations
Stirrat, Colin G
Alam, Shirjel R
MacGillivray, Thomas J
Gray, Calum D
Dweck, Marc R
Raftis, Jennifer
Jenkins, William SA
Wallace, William A
Pessotto, Renzo
Lim, Kelvin HH
Mirsadraee, Saeed
Henriksen, Peter A
Semple, Scott IK
Newby, David E
Ferumoxytol-enhanced magnetic resonance imaging assessing inflammation after myocardial infarction
title Ferumoxytol-enhanced magnetic resonance imaging assessing inflammation after myocardial infarction
title_full Ferumoxytol-enhanced magnetic resonance imaging assessing inflammation after myocardial infarction
title_fullStr Ferumoxytol-enhanced magnetic resonance imaging assessing inflammation after myocardial infarction
title_full_unstemmed Ferumoxytol-enhanced magnetic resonance imaging assessing inflammation after myocardial infarction
title_short Ferumoxytol-enhanced magnetic resonance imaging assessing inflammation after myocardial infarction
title_sort ferumoxytol-enhanced magnetic resonance imaging assessing inflammation after myocardial infarction
topic Special Populations
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5629948/
https://www.ncbi.nlm.nih.gov/pubmed/28642288
http://dx.doi.org/10.1136/heartjnl-2016-311018
work_keys_str_mv AT stirratcoling ferumoxytolenhancedmagneticresonanceimagingassessinginflammationaftermyocardialinfarction
AT alamshirjelr ferumoxytolenhancedmagneticresonanceimagingassessinginflammationaftermyocardialinfarction
AT macgillivraythomasj ferumoxytolenhancedmagneticresonanceimagingassessinginflammationaftermyocardialinfarction
AT graycalumd ferumoxytolenhancedmagneticresonanceimagingassessinginflammationaftermyocardialinfarction
AT dweckmarcr ferumoxytolenhancedmagneticresonanceimagingassessinginflammationaftermyocardialinfarction
AT raftisjennifer ferumoxytolenhancedmagneticresonanceimagingassessinginflammationaftermyocardialinfarction
AT jenkinswilliamsa ferumoxytolenhancedmagneticresonanceimagingassessinginflammationaftermyocardialinfarction
AT wallacewilliama ferumoxytolenhancedmagneticresonanceimagingassessinginflammationaftermyocardialinfarction
AT pessottorenzo ferumoxytolenhancedmagneticresonanceimagingassessinginflammationaftermyocardialinfarction
AT limkelvinhh ferumoxytolenhancedmagneticresonanceimagingassessinginflammationaftermyocardialinfarction
AT mirsadraeesaeed ferumoxytolenhancedmagneticresonanceimagingassessinginflammationaftermyocardialinfarction
AT henriksenpetera ferumoxytolenhancedmagneticresonanceimagingassessinginflammationaftermyocardialinfarction
AT semplescottik ferumoxytolenhancedmagneticresonanceimagingassessinginflammationaftermyocardialinfarction
AT newbydavide ferumoxytolenhancedmagneticresonanceimagingassessinginflammationaftermyocardialinfarction